Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Alergiisa Da Imunologii… | Healthcare Services | 31.6% | 91st pct | 268 |
| Estetikis Tsentri MM | Healthcare Services | 26.4% | 87th pct | 268 |
| Inovatsiuri Sameditsino… | Healthcare Services | 7.5% | 43rd pct | 268 |
| Med-Diagnostika | Healthcare Services | — | no FY data | 268 |
| Kartul-Amerikuli Reprod… | Healthcare Services | — | no FY data | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 3 of 5 peers filed FY2024. Switch to FY2023 (4 of 5).
| Ratio — FY 2024 | Alergiisa Da Imunologii… | Inovatsiuri Sameditsino… | Estetikis Tsentri MM | Med-Diagnostika | Kartul-Amerikuli Reprod… |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 52.9% | 35.9% | 60.3% | — | — |
| EBITDA Margin | 31.6% | 7.5% | 26.4% | — | — |
| EBITDAR | 1,847 | 759 | 1,311 | — | — |
| EBITDAR Margin | 31.6% | 14.4% | 27.1% | — | — |
| EBIT Margin | 28.0% | 5.6% | 23.1% | — | — |
| Net Profit Margin | 25.1% | 5.9% | 19.9% | — | — |
| Operating Expense % of Sales | 21.4% | 28.4% | 33.9% | — | — |
| Returns | |||||
| Return on Assets (ROA) | 14.3% | 13.9% | 33.2% | — | — |
| Return on Equity (ROE) | 26.3% | 17.5% | 34.7% | — | — |
| ROIC [EBIT / Invested Capital] | 17.1% | 16.2% | 48.4% | — | — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 41.1% | 4.5% | 1.6% | — | — |
| Debt-to-Equity | 0.76x | 0.06x | 0.02x | — | — |
| Debt-to-EBITDA | 2.29x | 0.25x | 0.04x | — | — |
| Equity-to-Assets | 54.4% | 79.4% | 95.9% | — | — |
| Net Debt | 3,991 | 50 | -464 | — | — |
| Cash & Equivalents | 231 | 50 | 510 | — | — |
| Total Debt | 4,222 | 100 | 46 | — | — |
| Liquidity & working capital | |||||
| Current Ratio | 6.10x | 4.85x | 159.60x | — | — |
| Quick Ratio | 6.10x | 4.85x | 159.60x | — | — |
| Cash Ratio | 0.95x | 0.11x | 45.48x | — | — |
| Total Current Assets | 1,478 | 2,247 | 1,788 | — | — |
| Total Current Liabilities | 242 | 464 | 11 | — | — |
| Inventory | N/A | N/A | N/A | — | — |
| Trade Receivables | 284 | 54 | 344 | — | — |
| Trade Payables | 239 | 234 | 11 | — | — |
| Net Working Capital | 1,236 | 1,783 | 1,777 | — | — |
| Net Working Capital % of Revenue | 21.1% | 33.9% | 36.8% | — | — |
| Trade Working Capital | 44 | -180 | 332 | — | — |
| Trade Working Capital % of Revenue | 0.8% | -3.4% | 6.9% | — | — |
| Change in Trade Working Capital | N/A | N/A | N/A | — | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | — | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | — | — |
| Receivables Turnover | 20.64x | 97.46x | 14.06x | — | — |
| Days Sales Outstanding (DSO) | 17.7 | 3.7 | 26.0 | — | — |
| Payables Turnover | 11.51x | 14.43x | 171.31x | — | — |
| Days Payable Outstanding (DPO) | 31.7 | 25.3 | 2.1 | — | — |
| Cash Conversion Cycle | -14.0 days | -21.6 days | 23.8 days | — | — |
| Asset Turnover | 0.57x | 2.34x | 1.67x | — | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 1,288 | N/A | N/A | — | — |
| Free Cash Flow (OCF − Capex proxy) | -1,754 | N/A | N/A | — | — |
| Cash Conversion (OCF / EBITDA) | 69.7% | N/A | N/A | — | — |
| Dividends Declared | N/A | N/A | N/A | — | — |
| Dividend Payout Ratio | N/A | N/A | N/A | — | — |